Scroll Down

  • Home

  • >
  • Neurodegenerative

  • >
  • Heuron AgingCare Suite™

  • >
  • Heuron IPD

Heuron IPD

Assists in the diagnosis of Parkinson’s disease by analyzing the nigrosome area on
brain MRI.
MFDS Approved CE Marked

Heuron IPD Brochure

  • MRI Analysis

  • Assessment in the
    asymptomatic stage

  • High Sensitivity
    and Specificity

Workflow Improvement

Detects early signs of Parkinson's disease through the analysis of dopaminergic neuron damage in the nigrosome area on brain MRI. Differentiates Parkinson’s from other movement disorders that do not exhibit the loss of dopaminergic neurons.

Supported Features

Detects and visualizes the nigrosome area on Susceptibility Map-Weighted Imaging (SMWI) to analyze the presence or absence of degeneration of dopaminergic neurons.

High Diagnostic Performance

Heuron IPD provides essential support for
the rapid and accurate quantification of nigral hyperintensity,
assisting in the diagnosis of idiopathic Parkinson's disease
and the prediction of symptom severity.

*Source:
1. Clinical usefulness of 18F FP-CIT PET/CT in suspicious early
Parkinson’s disease with comparative effectiveness research,
NECA, 2015
2. Clinical Study involving 10 institutions, 2020

Heuron IPD

Parkinson’s Disease Dignostic-Aid

Explore the product's features firsthand by clicking directly on your screen.

L
R

1 / 2

Discover more with our demo.

TOP